IWAG
MTNB icon

Integer Wealth Advisors Group’s Matinas BioPharma MTNB Stock Holding History

Integer Wealth Advisors Group’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,156
Closed -$82K – 66
2019
Q4 		$82K Buy
+1,156
New +$67K 0.08% 63

Other funds holding MTNB

BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Integer Wealth Advisors Group's MTNB Position: Q1 2020 in Review

Integer Wealth Advisors Group sold out of Matinas BioPharma (MTNB) in Q1 2020, closing a stake of 1,156 shares — an estimated $82K sold.

Integer Wealth Advisors Group first reported a position in MTNB in Q4 2019 and held it in 1 quarter. The position peaked at $82K in Q4 2019. 68 funds tracked by Wall St. Rank hold MTNB as of Q1 2020.

  • Integer Wealth Advisors Group reported no remaining Matinas BioPharma position as of Q1 2020 after selling out during the quarter.
  • Integer Wealth Advisors Group sold 1,156 Matinas BioPharma shares in Q1 2020, an estimated $82K.
  • Integer Wealth Advisors Group first reported a position in Matinas BioPharma in Q4 2019 and held it in 1 quarter.
  • Integer Wealth Advisors Group's Matinas BioPharma position peaked at $82K in Q4 2019.
  • 68 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2020.

Based on Integer Wealth Advisors Group's 13F filing for Q1 2020, filed 11 May 2020.